Dr. Zhang Yan is the Associate Professor of School of Biomedical Engineering. Her research has long centered on systematically elucidating the mechanisms underlying aberrant differentiation of disease-associated immune cells, with a specific focus on the molecular basis of macrophage polarization and tumor microenvironment remodeling. Building on these mechanistic insights, her group have identified novel therapeutic targets and pursued translational immunotherapy research. These findings have been published in leading journals including Cancer Research (2015), Cell Research (2018, 2024), and Advanced Science (2023, 2024, 2025).

12/2007-6/2012        Postdoc, Department of Microbiology and Immunology,

                                          Weill Medical College of Cornell University

12/2005-11/2007      Postdoc, Musculoskeletal Research Center, Hospital for Joint Disease

                                        School of Medicine   New York University

9/2000-7/2005          Ph.  D., School of Medicine, Shandong University

                                        Major in Biochemistry and Molecular Biology

9/1994-7/1999          M. D., School of Medicine, Shandong Medical University 

                                        Major in Clinic Medicine

7/2012- Present       Associated Professor, School of Biomedical Engineering,

                                         Shanghai Jiaotong University 

6/2005-12/2005       Instructor, School of Medicine

                                   Shandong University

Abnormal differentiation of myeloid cells in pathological conditions.

Editorial Aboard of Global Medical Genetics (2021-present);

1. Wang LH #, Zhu J#, Ding ZQ, Xie ZY, Liu XC, Zhang FH, Meng XX, Liu XJ*, Zhang Y*, Ding XT *; Immune Predictors of Radiotherapy Outcomes in Cervical Cancer, Advanced Science, 2026, 13(16): e09784   (IF=15.1)

2. Zhang Y*, Wang ZE, Lu Y, Sanchez J.D, Li JJ, Wang LH, Meng XX, Zhong M*, Gao WQ*, Ding XT*. Region-specific CD16+ neutrophils promote colorectal cancer progression by inhibiting natural killer cells, Advanced Science, 2024, 11(29):e2403414    (IF=15.1)

3. Lin HP, Luo Y, Gong TY, Fang HS, Li H, Ye GY, Zhang Y*, Zhong M*. GDF15 induces chemoresistance to oxaliplatin by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis in colorectal cancer, Cell Oncolgoy, 2024, 47(4):1149  (IF=4.9)

4. Qu JW, Li DW, Jin JS, Sun N, Wu JJ, Zhang Y*, Yuan XD*, Zhang M*. Hypoxia-Inducible Factor 2a Attenuates Renal Ischemia-Reperfusion Injury by Suppressing CD36-Mediated Lipid Accumulation in Dendritic Cells in a Mouse Mode Base editing effectively prevents early-onset severe cardiomyopathy in Mybpc3 mutant mice, J Am Soc Nephrol, 2023, 34(1):73 (IF=8.65)

5. Wang C, Zhang Y*, Gao WQ*. The involving role of immune cells in prostate cancer, Cancer Letters, 2022, 252:9-12    (IF=9.7)

6. Fang HS#，Huang YZ#，Luo Yang # ，Tang JY，Yu MH，Zhang Y*，Zhong M*, SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4/CXCL12 axis. Cell Immunology, 2022, 371:104458     (IF=4.868)

7. Xu YJ#, Chen JJ#, Huang YZ, Luo Y, Hsieh AC, Li H, Wei XB*, Gao WQ*, Zhong M*, Zhang Y*. Patient-derived organoids in cellulosic sponge model chemotherapy response of metastatic colorectal cancer, Clin Transl Med, 2021, 11(1):e285    (IF=11.492)

8. Fang HS#，Huang YZ#，Luo Yang # ，Tang JY，Yu MH，Zhang Y*，Zhong M*, SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4/CXCL12 axis. Cell Immunology, 2022, 371:104458     (IF=4.868)

9. Lu Y #, Huang YZ #, Huang Lei #, Xu YJ, Wang ZE, Li H, Zhang T, Zhong M*, Gao WQ*, Zhang Y*. CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients, BMC Immunology, 2020, 21;46   (IF=3.615)

10. Wang Chao; Chen Jiahuan; Zhang Qianfei; Li Wang; Zhang Shengbo; Xu Yanjie; Wang Fang; Zhang Bing; Zhang Yan*; Gao Wei-qiang*; Elimination of CD4lowHLA-G+ T cells overcomes castrationresistance in prostate cancer therapy, Cell Research, 2018, 28(11): 1103-1117   (IF=11.615)